Business
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
CAMBRIDGE, Mass., February 18, 2026--Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity
About this update from Vyome Holdings, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":368,"height":350,"url":"https://media.zenfs.com/en/business-wire.com/2452950d1ac33b4b15b5d5782d2bf805"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LIVVMsOq5EnOEVfaaP8LYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY3MTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2452950d1ac33b4b15b5d5782d2bf805","width":368,"height":350}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"VT-1908 was demonstrated to be effective as a topical steroid in the uveitis preclinical model and shows very good safety","length":121,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Plans to generate human clinical data using the India innovation corridor in a very cost-efficient manner","length":105,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"No change in capital deployment plan; laser focused on our lead program, VT-1953 (for treatment of malodor of MFW), Phase 3 study","length":129,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":355,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., February 18, 2026--(BUSINESS WIRE)--Vyome Holdings, Inc. ("Vyome") (Nasdaq: HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed Journal of Ophthalmic Inflammation and Infection, a Springer-Nature journal1.","length":341,"tagName":"p"},{"type":"text","content":"Uveitis refers to the immune-inflammation of the eye, and accounts for 10–15% of all cases of blindness in the developed world2. In the United States alone, it is associated with an estimated 30,0003 new cases of legal blindness annually, and represents an estimated $3 billion market opportunity by 20324. Topical steroids are the standard first line of treatment for uveitis. However, many patients experience inadequate response, and prolonged steroid use is associated with major complications, including cataract formation and increased pressure in the eye, leading to glaucoma.","length":583,"tagName":"p"},{"type":"text","content":"In this publication1, topical eye drops of VT-1908 resulted in the desired concentration of the active drug being achieved in the eye without any i...